Broncus Holding

Broncus Holding FCF per Share

The Free Cash Flow per Share of Broncus Holding (2216.HK) as of Nov 5, 2026 is -0.02 USD. In the previous year, Free Cash Flow per Share was -0.02 USD — a change of -14.97% (higher).

FCF per Share

-0.02USD

YoY

-14.97%

Last updated:

Free Cash Flow per Share of Broncus Holding is 2025 -0.02 USD. Free Cash Flow per Share of Broncus Holding was 2024 -0.02 USD. It decreases by -14.97% higher compared to the previous year.

The Broncus Holding FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2019
-0.04 USD
Jan 1, 2020
-0.09 USD
Jan 1, 2021
-0.10 USD
Jan 1, 2022
-0.08 USD
Jan 1, 2023
-0.06 USD
Jan 1, 2024
-0.02 USD
Jan 1, 2025
-0.02 USD
The Broncus Holding FCF per Share history
YEARFCF per ShareYoY
-0.02USD-14.97%
-0.02USD-61.56%
-0.06USD-15.76%
-0.08USD-27.75%
-0.10USD+20.47%
-0.09USD+143.24%
-0.04USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Broncus Holding Stock analysis

What does Broncus Holding do? Broncus Holding Corp generates revenue through the sale of medical device and consumable products across multiple therapeutic areas. The company's diagnostic solutions include FleXNeedle, ATV Sheath, and ATV Balloon, targeting healthcare providers for diagnostic procedures. Lung cancer treatment solutions feature InterVapor for lung cancer and H-Marker, sold to hospitals and oncology centers. Chronic obstructive pulmonary disease (COPD) solutions consist of InterVapor for COPD and TLD Ablation System, marketed to respiratory care facilities. Navigation platforms like Lungpoint, Lungpro, and New Generation Navigation Platform are supplied to medical institutions requiring advanced imaging guidance. The firm's product portfolio is structured around four key solution areas: diagnostics, lung cancer treatment, COPD management, and navigation systems. Diagnostic tools such as FleXNeedle and ATV products are used in minimally invasive procedures, while InterVapor serves dual purposes for both lung cancer and COPD applications. The TLD Ablation System is specifically designed for COPD treatment, and navigation platforms support precise procedural guidance in respiratory interventions. Broncus Holding Corp's primary customers are healthcare institutions including hospitals, specialized oncology centers, and respiratory care facilities. These entities purchase the company's medical devices and consumables for clinical use in treating respiratory conditions. The company's commercialization strategy focuses on direct sales to medical facilities rather than through third-party distributors, ensuring consistent product application and support. Broncus Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Broncus Holding stock

Free Cash Flow per Share of Broncus Holding is -0.02 USD in 2025.

Free Cash Flow per Share of Broncus Holding changed from -0.02 USD to -0.02 USD, representing a -14.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Broncus Holding since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Broncus Holding

All Key Metrics — Broncus Holding